Antiserum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man

Najarian, J S; Simmons, Richard L.; Gewürz, Henry; Moberg, A; Merkel, Frederick K.

doi:10.1097/00007890-197005000-00016

Cited by 10 publications

(12 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The original polyclonal ALGs (6,7) have been replaced by ever more specifically targeted monoclonal antibodies (mabs) (8)(9)(10)(11)(12). Waldmann and Hale (11,12) and first used for kidney transplantation by Calne et al (13) in combination with minimal cyclosporine-based maintenance immunosuppression.…”

Section: Introductionmentioning

confidence: 99%

Two Hundred Living Donor Kidney Transplantations Under Alemtuzumab Induction and Tacrolimus Monotherapy: 3-Year Follow-Up

Tan

Donaldson

Basu

et al. 2009

American Journal of Transplantation

View full text Add to dashboard Cite

Alemtuzumab has been used in off-label studies of solid organ transplantation. We extend our report of the first 200 consecutive living donor solitary kidney transplantations under alemtuzumab pretreatment with tacrolimus monotherapy and subsequent spaced weaning to 3 years of follow-up. We focused especially on the causes of recipient death and graft loss, and the characteristics of rejection. The actuarial 1-, 2-and 3-year patient and graft survivals were 99.0% and 98.0%, 96.4% and 90.8% and 93.3% and 86.3%, respectively. The cumulative incidence of acute cellular rejection (ACR) at the following months was 2% ≤6, 9.0% ≤12, 16.5% ≤18, 19.5% ≤24, 23.5% ≤30, 24.0% ≤36 and 25% ≤42. The mean serum creatinine (mg/dL) and glomerular filtration rate (mL/min/1.73 m 2 ) at 1 and 3 years were 1.4 ± 0.6 and 58.7 ± 21.6 and 1.5 ± 0.7 and 54.9 ± 20.9, respectively. Fifty (25%) recipients had a total of 89 episodes of ACR. About 88.7% of ACR episodes were Banff 1, and of those, 82% were steroid-sensitive. Nine (4.5%) recipients had antibodymediated rejection (AMR). About 76.5% were weaned but only 46% are currently on spaced dose (qod or less) tacrolimus monotherapy, and 94.4% remained steroidfree from the time of transplantation. Infectious complications were uncommon. This experience suggests the 3-year efficacy of this approach.

show abstract

Section: Introductionmentioning

confidence: 99%

Two Hundred Living Donor Kidney Transplantations Under Alemtuzumab Induction and Tacrolimus Monotherapy: 3-Year Follow-Up

Tan

Donaldson

Basu

et al. 2009

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Perhaps the most extensively tested anti lymphocyte globulin is MALG, which was introduced in 1969 [17], Early data on MALG appeared to show no adverse hema tological consequences of its administration to human subjects [16][17][18]. However, nu unexpected postoperative hemorrhages due to surgical or medical complications, the use of'least-incompatible' blood for transfusion may be necessary in patients receiving MALG.…”

Section: Discussionmentioning

confidence: 99%

Passively Acquired Antibody Directed at Human Erythrocytes Seen during Therapy with Minnesota Antilymphohlast Globulin

Wick¹,

DeLong²,

Moore³

1985

Vox Sanguinis

View full text Add to dashboard Cite

6 renal transplant patients, seen at the Mayo Clinic between July 1982 and April 1983, received Minnesota antilymphoblast globulin (MALG) for treatment of allograft rejection and demonstrated warm-acting ‘auto’-antibodies during such therapy. These antibodies represented xenogeneic reactivity in equine MALG, rather than the products of patient-derived immune responses, since they were not detected before or after the period of therapy with this immunosuppressive agent in any of the 6 cases. They interfered with crossmatch procedures for red cell transfusion, and were only variably removed by autoabsorption techniques. Heat treatment of sera containing MALG-related red cell antibodies was ineffective in abrogating their reactivity and also compromised the reactivity of some red cell alloantibodies which were tested as controls. Transfusion of ‘least-incompatible’ red blood cells had no adverse effects in 2 cases where it was necessitated by clinical circumstances, despite an inability to obtain suitable serological samples for crossmatching

show abstract

“…These experiments were initiated in part to analyze the peculiar hyporesponsiveness to horse proteins in patients receiving HoALG even in ab sence of other immunosuppressive agents [1,21,22]. It was felt that either the route of administration (i.v.…”

Section: Discussionmentioning

confidence: 99%

“…or i.rn. with 10 mg HoGG kg/day, a dose selected to resemble that given humans re ceiving HoALG at various centers [2,3,21]. A marked immune response was observed in 7 of 8 animals, with rapid immune elimination of antigen, formation of antibody and hypocomplementemia.…”

Section: Discussionmentioning

confidence: 99%

Reactivities to Horse Anti-Lymphocyte Globulin

Johnson¹,

Gewurz²,

Moberg³

et al. 1971

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The immune response of adult rabbits to daily doses of horse γ-globulin (HoGG) administered intravenously or intramuscularly in various tolerance-inducing regimens was investigated. Circulating HoGG, anti-HoGG antibodies, and hemolytic complement (C) levels were measured daily. High dose tolerance, as defined by antigen elimination, was achieved by both routes with 100, but not 10, mg HoGG/kg body weight/day. There was an initial accumulation of large amounts of HoGG during the 1st week. The HoGG titer decreased markedly during weeks 2 and 3 in association with the appearance of agglutinating and precipitating anti-HoGG antibody in most of the animals. However, by the 4th week detectable antibody formation against certain of the HoGG antigens ceased and the HoGG concentration again began to rise. Antibodies to at least one HoGG antigen persisted while ‘tolerance’ to at least two other HoGG antigens had been induced. Serum C levels showed close correlation with HoGG levels, such that marked hypocomplementemia was seen during the immune phase of weeks 2 and 3, and normal or elevated C levels were observed when HoGG levels rose to the high ‘tolerant’ values. Pretreatment with centrifuged deaggregated HoGG 7 days prior to the daily regime led to accumulation of each of the 3 HoGG antigens without a demonstrable immune phase; antigen levels constantly were high, circulating antibodies could not be detected and hypocomplementemia was avoided. Administration of horse anti-rabbit lymphocyte serum in association with HoGG led to a greatly increased catabolism of the HoGG, an early appearance of anti-HoGG antibodies and absence of tolerance to any HoGG antigens. These observations add descriptive data on the interplay between antigen, antibody and C during the induction of high-dose tolerance, and have aided in interpreting the response of humans to HoGG and horse anti-lymphocyte globulin (HoALG). They are consistent with the hypothesis that dosages of HoGG commonly used in the administration of HoALG to man favor the induction of tolerance to HoGG via the mechanism of ‘immunologic paralysis’ or ‘high-dose tolerance’.

show abstract

Antiserum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man

Cited by 10 publications

References 1 publication

Two Hundred Living Donor Kidney Transplantations Under Alemtuzumab Induction and Tacrolimus Monotherapy: 3-Year Follow-Up

Two Hundred Living Donor Kidney Transplantations Under Alemtuzumab Induction and Tacrolimus Monotherapy: 3-Year Follow-Up

Passively Acquired Antibody Directed at Human Erythrocytes Seen during Therapy with Minnesota Antilymphohlast Globulin

Reactivities to Horse Anti-Lymphocyte Globulin

Contact Info

Product

Resources

About